Bnt327 — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

8 Recruiting

0 Completed trials

2 Sponsors

10 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 1 Phase II/III: 1 Phase II: 2 Phase I/II: 5

Indications tested

Non-small cell lung cancer stage IIIA 3 Non-small cell lung cancer stage III 3 Non-small cell lung cancer stage IV 3 Non-small cell lung cancer metastatic 3 Non-small cell lung cancer stage IIIB 3 Non-small cell lung cancer 2 Small cell lung cancer 1 Squamous cell carcinoma of lung 1 Breast cancer 1 Ovarian cancer 1 Squamous cell carcinoma of head and neck 1 HER2 mutant non-small cell lung cancer 1

Sponsors using this IMP

BioNTech SE 8 Dualitybio Inc. 1

All trials

9 total

DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending

2025-523895-22-00 Phase II 5 countries Dualitybio Inc.
A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad… Recruiting

2024-520238-31-01 Phase I/II 4 countries BioNTech SE
A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with… Recruiting

2024-519344-32-00 Phase I/II 4 countries BioNTech SE
A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa… Recruiting

2024-517979-20-00 Phase I/II 3 countries BioNTech SE
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 Phase III 7 countries BioNTech SE
A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment pumit… Recruiting

2025-521768-36-00 Phase I/II 2 countries BioNTech SE
A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting

2024-517261-16-00 Phase I/II 4 countries BioNTech SE
Safety and preliminary efficacy of pumitamig (BNT327), an investigational therapy for patients with non-small cell lung cancer in combinatio… Recruiting

2024-518279-80-00 Phase II 1 country BioNTech SE
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Phase II/III 9 countries BioNTech SE

Showing 1–9 of 9 trials

← All drugs A–Z